Wednesday, June 10, 2026

pharma Β· Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Bayer | Pharmaceuticals

Bayer | Pharmaceuticals clinical programs β€” 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Berlin, DE HQ
4 Employees
TGA registrant Type
Company details
Status
Public
HQ
Berlin, DE
Employees
4
Programs
2
Drugs
15
Patents
1
Intelligence Β· Clinical Programs

Bayer | Pharmaceuticals projects

2 ClinicalTrials.gov programs sponsored by Bayer | Pharmaceuticals.

Bayer | Pharmaceuticals has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 22049

    Bayer Australia Ltd

    Advanced metastatic castration-resistant prostate cancer with prostate specific membrane antigen (PSMA) expression

    phase 1 other active

    1 trial
  2. BEYONTTRA 356 mg film-coated tablets

    Bayer Australia Ltd

    Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Bayer | Pharmaceuticals have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.